Y mAbs Therapeutics
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $356.85 million
- Book Value:
- Revenue TTM:
- $75.03 million
- Operating Margin TTM:
- Gross Profit TTM:
- $57.70 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Y mAbs Therapeutics had its IPO on 2018-09-21 under the ticker symbol YMAB.
The company operates in the Healthcare sector and Biotechnology industry. Y mAbs Therapeutics has a staff strength of 147 employees.
Shares of Y mAbs Therapeutics opened at $7.92 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $7.56 - $8.18, and closed at $8.17.
This is a +5.01% increase from the previous day's closing price.
A total volume of 274,600 shares were traded at the close of the day’s session.
In the last one week, shares of Y mAbs Therapeutics have slipped by -15.07%.
Y mAbs Therapeutics's Key Ratios
Y mAbs Therapeutics has a market cap of $356.85 million, indicating a price to book ratio of 2.056 and a price to sales ratio of 5.2098.
In the last 12-months Y mAbs Therapeutics’s revenue was $75.03 million with a gross profit of $57.70 million and an EBITDA of $-57817000. The EBITDA ratio measures Y mAbs Therapeutics's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Y mAbs Therapeutics’s operating margin was -78.16% while its return on assets stood at -22.32% with a return of equity of -55.7%.
In Q1, Y mAbs Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 93.1%.
Y mAbs Therapeutics’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.6 per share while it has a forward price to earnings multiple of 119.0476 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Y mAbs Therapeutics’s profitability.
Y mAbs Therapeutics stock is trading at a EV to sales ratio of 2.5226 and a EV to EBITDA ratio of -0.8522. Its price to sales ratio in the trailing 12-months stood at 5.2098.
Y mAbs Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $137.45 million
- Total Liabilities
- $25.92 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Y mAbs Therapeutics ended 2023 with $137.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $137.45 million while shareholder equity stood at $107.83 million.
Y mAbs Therapeutics ended 2023 with $0 in deferred long-term liabilities, $25.92 million in other current liabilities, 4000.00 in common stock, $-442433000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $92.63 million and cash and short-term investments were $92.63 million. The company’s total short-term debt was $855,000 while long-term debt stood at $0.
Y mAbs Therapeutics’s total current assets stands at $124.01 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $18.70 million compared to accounts payable of $8.84 million and inventory worth $8.95 million.
In 2023, Y mAbs Therapeutics's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Y mAbs Therapeutics paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Y mAbs Therapeutics stock is currently trading at $8.17 per share. It touched a 52-week high of $20.48 and a 52-week low of $20.48. Analysts tracking the stock have a 12-month average target price of $12.71.
Its 50-day moving average was $6.85 and 200-day moving average was $7.63 The short ratio stood at 3.99 indicating a short percent outstanding of 0%.
Around 1234.3% of the company’s stock are held by insiders while 6180.8% are held by institutions.
Frequently Asked Questions About Y mAbs Therapeutics
Similar Industry Stocks (Biotechnology)
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.